Reinduction(4weeks)
Phase 2Small molecule
Reinduction(4weeks) is one of 25 small molecule programs targeting Childhood Acute Lymphoblastic Leukemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Childhood Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Fludara
SanofiApproved
Cerubidine
HHikma Pharmaceuticals LLC
Approved
Anerem
AAcacia Pharma Ltd
Approved
Monurol
MMeitheal
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Adriamycin
PfizerPhase 3
Zinecard
PfizerPhase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Blincyto
AmgenPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Reinduction(4weeks). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHo Joon Im